Articles tagged with Regulatory T Cells
Researchers identified the spleen as a key control center for transplant tolerance, triggering donor-specific regulatory T cells to calm the immune response. This targeted approach induces controlled, donor-specific state in T cells, preserving body's ability to fight infections while supporting long-term graft acceptance.
Researchers from MSK discovered that two distinct subtypes of regulatory T cells play opposing roles in colorectal cancer, with one restraining tumor growth and the other fueling it. The study suggests that selective approaches to targeting these cells could improve immunotherapy treatment for most patients with colorectal cancer.
Researchers at MSK found that Foxp3 degradation can inhibit cancer growth and enhance immune response. They also developed a system to detect loss of heterozygosity during gene editing, which is a common problem in DNA double-strand breaks.
Researchers at Gladstone Institutes and UCSF have identified the genetic switches that regulate FOXP3 levels in human and mouse cells. In humans, multiple enhancers work together to keep FOXP3 active, while a repressor keeps it off in conventional T cells. This discovery has important implications for developing immune therapies.
Researchers at St. Jude Children's Research Hospital found that metabolism guides the activation states of regulatory T cells, which dampen inflammation. The study reveals a link between mitochondrial function and lysosome activity in controlling these immune cells.
Research from the University of Chicago shows that a specially trained population of immune cells, called peacekeeper cells, prevents other immune cells from attacking their own cells during infection. This specificity allows the immune system to distinguish between foreign and self-antigens, preventing autoimmune attacks.
Researchers identified nine distinct types of T cells that harbor inactive HIV cells, and persistent T cells with HIV even after antiretroviral therapies. This discovery brings medical experts closer to a cure for the infection affecting nearly 40 million people globally.
Researchers at Osaka University developed a new technique called single-cell suppressive profiling of regulatory T cells (scSPOT) that can pinpoint the effects of Tregs on all other immune cells. The study found that Tregs most strongly affect CD8-EM T cells, which play a key role in fighting cancer and infections.
Researchers developed a computer model called MANAscore to identify tumor-fighting immune cells in lung cancer patients treated with immune checkpoint inhibitors. The three-gene model helped find differences associated with patient response to immunotherapy, including the presence of stem-like memory T cells.
A new study finds that excess RELMb protein in the intestine disrupts tolerance to triggering foods and increases the risk of food allergy. Inhibiting RELMb may lead to a cure or prevention of food allergy, offering a promising therapeutic approach.
Researchers at Tokyo University of Science found that kaempferol increases RALDH2 levels in dendritic cells, promoting regulatory T-cell development and reducing inflammation. The study suggests that flavonoids like kaempferol may serve as natural remedies to alleviate allergic symptoms.
Researchers at Gladstone Institutes and UCSF identified MED12 as a crucial switch that regulates T cell rest and activation. The study found that MED12 promotes rest in resting cells and activation in activated cells, and its removal led to blurred lines between rest and activation.
Research suggests that T-cell receptor repertoire analysis can inform treatment responses and predict efficacy in combination therapies for HCC. Advances in sequencing technologies are refining our understanding of tumor-immune interactions and adaptive immune mechanisms.
Researchers found that EZH2 inhibition boosts T-cell immunotherapies' effectiveness by making cancer cells more visible and reducing immunosuppressive regulatory T-cells. This combination therapy showed improved survival rates in mice with lymphomas, suggesting a potential new approach to treating certain cancers.
Researchers discovered that virally infected neurons promote TH1 cell development and inhibit TH2 cells through neuropeptide signaling, crucial for controlling viral infections. This finding establishes a novel link between infected tissue and T cell subset differentiation.
Researchers at MD Anderson Cancer Center present promising new treatments, including a gastric cancer therapy using T cell antigen coupler technology. Additionally, COVID-19 mRNA vaccines are shown to improve responses to immune checkpoint inhibitors in patients with non-small cell lung and melanoma cancers.
Researchers found that fever temperatures increase helper T cell metabolism, proliferation and inflammatory activity, while causing mitochondrial stress, DNA damage and cell death in a specific subset of Th1 cells. These findings may explain how chronic inflammation contributes to cancer development and suggest a fundamental way cells ...
Researchers have discovered that administering regulatory T cells (Tregs) can enhance tissue healing, promoting bone volume, muscle growth, and skin wound closure. The key role of interleukin-10 (IL-10) in supporting tissue repair has also been identified.
Researchers from Osaka University discovered that Ikaros binds to Foxp3 to inhibit the expression of target genes, including Ifng, in regulatory T cells. This interaction is crucial for maintaining immune homeostasis and preventing autoimmune disorders.
A preclinical study suggests that knocking out CD5 on CAR T cells boosts their anti-tumor efficacy against various cancers, including solid tumors. The researchers found that CD5 deletion enhances the function of CAR T cells by reining in immune responses and increasing cancer-cell-killing activity.
Researchers at University of Cambridge uncover unified healer army of regulatory T cells that constantly move and repair damaged tissue. This discovery has implications for treating various diseases, including autoimmune disorders and infectious diseases.
A new strategy for improving melanoma treatment involves targeting the communication between immune cells within the tumor. By neutralizing specific molecules, researchers found that CD8+ T cell activity against tumors increased while T regulatory cells' ability to inhibit the immune response decreased.
A new strategy used by cancer cells to protect themselves from immune system attack has been identified, and a potential target for immunotherapy has been found. Blocking activin receptor 1C on CD4+ T cells may help prevent the accumulation of immune-suppressing Tregs in tumors and slow tumor growth.
Researchers analyzed LTBR expression levels in various cancers, finding it associated with low patient survival and immune cell infiltration. The study identified LTBR as a potential target for cancer immunotherapy and marker of poor prognosis.
Researchers have revealed CD4+ T cells can work effectively on their own to control melanoma, challenging conventional understanding. Harnessing their potential therapeutically holds great promise for improving current cancer immunotherapies.
Researchers at UMass Amherst have discovered that tumor cells outwit the body's immune system by incorporating cytoplasmic material into their own T cells. This 'mosquito effect' helps cancerous tumors evade the immune system, making it a promising area of study for developing more effective treatments.
A U of M-led study introduces an innovative genetic engineering method that avoids cost and safety concerns associated with viral vectors. The method combines CRISPR-Cas9 precision genome editing and a novel DNA integration mechanism, integrating large DNA sequences into human T-cells with high efficiency.
Researchers mapped transcription factors in T cells infiltrating tumors, finding ways to increase anticancer efficacy by promoting or blocking T-cell differentiation. The findings have implications for cancer immunotherapy and provide new potential strategies to enhance immunotherapy.
Salk researchers identify Foxp3 as the protein that determines regulatory T cell genome structure and fate, enabling manipulation to treat autoimmunity or fight cancer. The study reveals Foxp3's essential role in creating unique chromatin architecture of regulatory T cells.
Scientists at the University of Würzburg have observed a new behavior of regulatory T cells, which remain in certain lymph nodes for months and function as local memory banks of the immune system. This discovery could lead to therapeutic applications in allergies and autoimmune diseases.
A groundbreaking study sheds light on the intricate mechanism behind the immune system's ability to differentiate between self and non-self antigens. Continuous activation of self-reactive T cells is essential for maintaining equilibrium and self-tolerance through regulatory T cells.
Scientists at Johns Hopkins Medicine have identified a protein mutation in CD8+ T cells that can make them more effective against cancer and infections. The mutated T cells were found to be more active when stimulated, persist longer, and expand in great numbers during the initial immune response.
Researchers developed a new strategy for T-cell-based immunotherapy using aptamers, which directly activates immune cells against cancer cells without genetic modifications. The innovative regulatory circuit establishes an artificial interaction between T cells and cancer cells.
Researchers discovered cytoplasmic retinoic acid receptors, such as RARalpha, are essential for T cell linking sensing at the cell surface with downstream signaling cascades and gene expression programs. The study sheds new light on TCR signaling and its connection to cancer treatment.
Researchers at La Jolla Institute for Immunology and Augusta University have identified a link between
Researchers at Purdue University and NIH have identified 14 understudied T-reg proteins with molecular roles in disease onset, offering new avenues for understanding autoimmune diseases and cancer. Studying these proteins could lead to the development of cell-based therapies to modify their functions.
A study found that patients with atopic dermatitis have a higher proportion of proinflammatory effector T cells and lower suppressive Tregs specific to a particular mite antigen, leading to the development of atopic symptoms.
A recent study led by Children's Hospital of Philadelphia identifies two different regulatory T cell populations, one related to autoimmunity and the other to protective immunity. The findings could pave the way for new treatments that target the immune system selectively.
A team at UC San Diego developed a biodegradable polymer system to treat rheumatoid arthritis by working with the immune system. The method uses encapsulated all-trans retinoic acid (ATRA) that transforms disease-causing cells into regulatory T cells.
Researchers at Hokkaido University discovered itaconate's modulatory effect on T helper and T regulatory cells, potentially leading to new treatments for autoimmune diseases. The study found that itaconate inhibits Th17 cell differentiation and promotes Treg cell development, reducing disease symptoms in mice models.
Researchers at Osaka University found that male patients with COVID-19 have a faster loss of circulating Treg cells, leading to dysregulated antibody responses. Females, on the other hand, have higher levels of these cells, which may help protect them from infection.
A study by University of Liverpool researchers reveals how a unique subset of lung T regulatory cells provide resistance to bacteraemic pneumonia. These cells, known as TNFR2 expressing Tregs, play a critical role in maintaining and controlling frontline host immune responses when pneumococci infect the lungs. The findings have signifi...
Regulatory T cells suppress self-reactive T cells by controlling protein synthesis, maintaining immune tolerance and preventing autoimmunity. A small molecule inhibitor called RocA also shows promise in mitigating inflammatory responses.
A study published in Science Immunology has discovered a potential new approach for treating systemic lupus erythematosus (SLE) by targeting iron metabolism in immune system cells. Blocking the iron uptake receptor reduced disease pathology and promoted anti-inflammatory regulatory T cell activity in a mouse model of SLE.
Researchers at the University of Pittsburgh discovered that exhausted cancer-fighting T cells can become immunosuppressive when working in low-oxygen tumor environments. Targeting these conditions can reinvigorate these cells, improving response to immune-based cancer therapies.
A small test group has shown that using a patient's own cells in combination with regulatory T-lymphocyte and IL-2 treatment can safely and effectively slow or halt the progression of amyotrophic lateral sclerosis (ALS). This treatment approach was found to be tolerable and biologically active over a period of one year.
In a new study, researchers found that immune T cells lacking the key transcription factor Satb1 are more susceptible to suppression by regulatory T cells, leading to transplant tolerance. The study provides insight into the mechanism behind transplantation tolerance and may lead to the development of new immunosuppression regimens.
Researchers at MUSC found that extracting and isolating Treg cells and transplanting them back into the same system successfully treats osteogenesis imperfecta for a year. The treatment results in stronger bones, increased osteoblast numbers, and decreased osteoclast numbers.
A new study reveals that certain food proteins can cause white blood cells to become dysfunctional, leading to immune intolerance. Researchers found that the gut-associated-lymphoid tissue is a suppressive environment where lymphocytes undergo arrested development, preventing dangerous immune reactions to food.
A novel subset of CD8+ regulatory-like T cells (CD8+TRLs) has been identified as 'first responders' to stroke, providing fast-acting and lasting protection. These cells reach the brain within 24 hours after stroke onset, releasing molecules that provide direct neuroprotective effects.
Researchers at the University of Liège discovered that Ly6C hi monocytes orchestrate balance between cytotoxic and regulatory properties of CD4 T cells. This understanding opens new therapeutic avenues for managing severe immunopathologies associated with respiratory viral infections.
Researchers created a detailed map of how immune genes function together, shedding light on the basic drivers of immune cell function and immune diseases. The study found interconnected regulatory networks that can help explain why mutations in different genes lead to the same disease or how drugs impact multiple immune proteins.
Scientists at Indiana University School of Medicine discovered differences in FOXP3 isoforms controlling Treg cells and their impact on the immune system. These findings may lead to new treatments for autoimmune diseases and allergies.
Researchers at the Salk Institute have identified an unexpected molecular target of a common treatment for alopecia, a condition where the immune system attacks hair follicles. They found that glucocorticoid hormones instruct regulatory T cells to activate hair follicle stem cells, leading to hair growth and regeneration.
Researchers at Kyoto University identified the mechanism behind active inflammation and immunosuppression in tumor microenvironments. EP2/EP4 inhibitors suppress tumor growth by allowing regulatory T cells to infiltrate and activate within tumors, benefiting patients with certain cancers.
Researchers develop targeted delivery system to boost regulatory T cells, which manage inflammation and reduce brain damage. The treatment increases IL2 levels, allowing regulatory T cells to survive and reducing cognitive impairment.
A study published in Nature Cardiovascular Research reveals that rare T cells targeting apolipoprotein B can contribute to inflammation and atherosclerosis progression. Researchers discovered these cells resemble regulatory T cells but develop a new identity as heart disease develops.
Researchers discovered that checkpoint inhibitors can activate regulatory T cells, which can counteract the immune response. Blocking PD-L1 enhanced effector Treg activity, reducing ability to control parasite infections. This finding highlights complexity of immune system's balance between controlling pathogens and protecting healthy ...
Researchers have shed light on how immune checkpoint protein LAG3 modulates T cell activity, providing crucial information for the development of new LAG3-blocking therapies. The study found that LAG3 suppresses T cell activation by disrupting coreceptor-Lck association, even in the absence of MHC Class II molecules.
WEHI researchers have found a way to release the 'handbrake' hold on Treg cells, enabling them to clear disease and infections faster. This breakthrough could lead to better treatment options for cancers and infections, where rapid clearance of unhealthy cells is crucial.